Skip to content

Effect of CPAP on blood pressure in pregnant women with SDB and preeclampsia: a Randomized Controlled Trial

Effect of CPAP on blood pressure in pregnant women with SDB and preeclampsia: a Randomized Controlled Trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065743
Enrollment
Unknown
Registered
2022-11-14
Start date
2022-11-21
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Disordered Breathing (SDB)

Interventions

intervention group:Continuous Positive Airway Pressure
control group:Conventional Therapy

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Pregnant women who agree to participate in the trial and sign an informed consent form meet all of the following conditions: 1. Aged 20-45 years; 2. Pregnant women between 26 and 34 weeks of gestation; 3. Suffer from SDB disease (AHI>=5 times/hour); 4. A diagnosis of preeclampsia (24-hour systolic blood pressure >140/90 mmHg and albuminuria >300mg) by an obstetrician-gynecologist; 5. Can tolerate CPAP therapy; 6. Consent to hospitalization in anticipation of treatment; 7. Meet expected treatment conditions; 8. Able to complete relevant tests and follow up.

Exclusion criteria

Exclusion criteria: 1. History of eclampsia in previous pregnancies; 2. Termination of pregnancy upon request without indications for termination of pregnancy; 3. DIC (INR > 2); 4. Platelet =125µmol/L, liver transaminase >=500IU/L); Pulmonary edema; Left heart failure); 6. Previous SDB treatment, such as CPAP, surgery, and oral orthotics; 7. Smoking, alcohol or drug addiction; Or is using psychotropic drugs, sedatives, narcotics, etc.; 8. The investigator did not consider it suitable to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
blood pressure;

Secondary

MeasureTime frame
soluble fms-like tyrosine kinase-1;placental growth factor;24-hour urinary protein;hepatic and renal function;platelet count;

Countries

China

Contacts

Public ContactLi Xinyi

Shanghai Sixth People's Hospital

lixinyilixinyi123@163.com+86 19804043355

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026